VIA
IDIX

Vantage Investment Advisors’s IDENIX PHARMACEUTICALS INC IDIX Stock Holding History

Vantage Investment Advisors’s Portfolio IDIX Stock Details IDIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-500
Closed -$3K – 722
2013
Q4 		$3K Buy
+500
New +$2.31K ﹤0.01% 571

Other funds holding IDIX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vantage Investment Advisors's IDIX Position: Q1 2014 in Review

Vantage Investment Advisors sold out of IDENIX PHARMACEUTICALS INC (IDIX) in Q1 2014, closing a stake of 500 shares — an estimated $3K sold.

Vantage Investment Advisors first reported a position in IDIX in Q4 2013 and held it in 1 quarter. The position peaked at $3K in Q4 2013. 96 funds tracked by Wall St. Rank hold IDIX as of Q1 2014.

  • Vantage Investment Advisors reported no remaining IDENIX PHARMACEUTICALS INC position as of Q1 2014 after selling out during the quarter.
  • Vantage Investment Advisors sold 500 IDENIX PHARMACEUTICALS INC shares in Q1 2014, an estimated $3K.
  • Vantage Investment Advisors first reported a position in IDENIX PHARMACEUTICALS INC in Q4 2013 and held it in 1 quarter.
  • Vantage Investment Advisors's IDENIX PHARMACEUTICALS INC position peaked at $3K in Q4 2013.
  • 96 funds tracked by Wall St. Rank held IDENIX PHARMACEUTICALS INC as of Q1 2014.

Based on Vantage Investment Advisors's 13F filing for Q1 2014, filed 1 May 2014.